MedTrace Logo

Treatment for Presumed Ocular Histoplasmosis

NCT01790893 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-06-16

No results posted yet for this study

Summary

The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.

Conditions

  • Ocular Histoplasmosis

Interventions

DRUG

aflibercept

Sponsors & Collaborators

  • John Kitchens, MD

    lead OTHER

Principal Investigators

  • John W Kitchens, MD · Retina Associates of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01790893 on ClinicalTrials.gov